Loading current stock analysis…
Loading current stock analysis…
India
Reported ownership for FY2027-Q2 as of 2026-09-30.
As of 06 Nov 2026, 03:30 pm
For the quarter ended September 30, 2026, Ipca reported consolidated net profit of ₹375.13 crore, a 32.5% year-on-year increase. Total income from operations rose to ₹2,909.94 crore (up from ₹2,788.10 crore in June 2026), while EBITDA margins expanded to 23%. Standalone profit after tax was ₹387.29 crore on income of ₹2,255.61 crore.
Yes. The subsidiary Unichem Laboratories recognized a provision of ₹24.26 crore for a UK legal claim related to perindopril. Additionally, the amalgamation with Krebs Biochemicals & Industries Ltd., resolved on June 26, 2026, has not yet been reflected in these financials pending necessary consents and approvals.
The stock closed at ₹1,938.20, down 0.6% from the previous close. While the weekly trend remains bullish, the daily Supertrend is bearish. Key resistance levels are near ₹1,945 and ₹1,995, with support at ₹1,902. Year-to-date returns stand at +38.6%, though the stock is currently in a -3.6% drawdown.
As of 06 Nov 2026, 03:30 pm
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price swings are higher than typical
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q2 FY27 and comparative quarterly trends.
| Metric | Q2 FY26 | Q1 FY27 | Q2 FY27(Latest) |
|---|---|---|---|
| Revenue From Operations | ₹2,557 crore | ₹2,788 crore | PEAK₹2,910 crore |
| Profit Before Tax | ₹392 crore | PEAK₹572 crore | ₹547 crore |
| Profit Loss For Period | ₹281 crore | PEAK₹424 crore | ₹389 crore |
| Basic Earnings Loss Per Share From Continuing And Discontinued Operations | ₹11.14 per share | PEAK₹15.84 per share | ₹14.79 per share |
Revenue from operations increased 13.8% year on year to ₹2,910 crore and 4.4% sequentially. Profit before exceptional items and tax was broadly flat QoQ at ₹571 crore as expenses rose faster than revenue; reported profit for the period declined 8.2% sequentially to ₹389 crore.
Cash flow from operating activities was ₹573 crore, above profit for the period of ₹389 crore. Free cash flow was ₹232 crore, while investing and financing activities recorded outflows of ₹341 crore and ₹252 crore, respectively.
Revenue grew strongly year on year, but sequential expense growth outpaced sales and left pre-exceptional profit broadly flat. The exceptional charge and higher tax accompanied a QoQ decline in reported profit, while operating cash flow exceeded earnings. Borrowings were lower than at both comparison dates, alongside higher inventories and receivables—working-capital movements to monitor as sales grow.
Exchange disclosures and regulatory announcements for IPCA Laboratories.
IPCA Laboratories Limited filed a copy of its Unaudited Financial Results for the second quarter and half year ended September 30, 2026, published in newspapers on November 6, 2026. The Board of Directors approved these results on November 5, 2026. For the quarter ended September 30, 2026, consolidated total income from operations was ₹2,909.94 Crores (up from ₹2,788.10 Crores in June 2026), with net profit after tax at ₹375.13 Crores. Standalone consolidated total income was ₹2,255.61 Crores, with profit after tax at ₹387.29 Crores.
IPCA LABORATORIES LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL
IPCA Laboratories Limited filed the transcript of its Q2 FY27 earnings conference call held on November 5, 2026. The company reported consolidated revenue growth of approximately 14% to INR2,910 crores and an improvement in consolidated EBITDA margins to 22.97%. Management reaffirmed full-year guidance for top-line growth at 14-16% and consolidated EBITDA margins at 22-23%, with expectations of annual margin expansion of 1-1.25%. Key operational highlights include a 32% growth in export formulations, strong performance in the Zerodol franchise (crossing INR1,500 crores), and the repayment of all foreign currency debt, leaving the company effectively debt-free with only INR155 crores in rupee term loans remaining.
Ipca Laboratories Limited’s Board of Directors, meeting in Mumbai on November 5, 2026, approved and took on record the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. Statutory auditors N V C & Associates LLP issued unmodified limited review reports on both sets of results. The filing discloses that the amalgamation of M/s. Krebs Biochemicals & Industries Ltd. with Ipca, resolved on June 26, 2026 with an appointed date of April 1, 2026, has not yet been reflected in these financials pending necessary consents/approvals.
Integrated Filing- Financials|Original|
Integrated Filing- Financials|Original|
IPCA Laboratories Limited provided an audio link for its conference call held on November 5, 2026, from 16:00 hrs (IST), to discuss the company’s Q2FY27 earnings and business update. The link is https://www.ipca.com/shareholders-information-conference-calls-concall-transcripts/#.
IPCA LABORATORIES LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL
Recent market and company developments associated with IPCA Laboratories.
Prabhudas Lilladher has issued a 'Buy' recommendation for Ipca Laboratories, setting a target price of Rs 2,200. This financial advice was published on Moneycontrol on November 6, 2026.
IPCA Laboratories reported a 32.5% year-on-year increase in Q2 consolidated net profit to ₹375 crore, driven by 13.8% revenue growth and an expansion of EBITDA margins to 23%. The results were supported by strong domestic and export formulation sales, although the subsidiary Unichem Laboratories recognized a ₹24.26 crore provision for a UK legal claim related to perindopril.
On November 5, 2026, Mahindra & Mahindra and IPCA Laboratories reported year-on-year profit growth in their standalone Q2 results, while Samvardhana Motherson saw a quarter-on-quarter decline. Bharat Forge also posted gains, with market reactions varying as stocks like BSE and Lenskart rose, whereas Nykaa and Cummins India slumped following their respective updates.
The Indian stock market is expected to open quietly on September 18, following mixed global cues. The Sensex ended slightly down, while the Nifty 50 was modestly up. Analysts suggest monitoring key resistance and support levels as geopolitical concerns persist.
At the same time, the fund is evaluating hospital expansion, hybrid diagnostics businesses and valuations to identify healthcare companies capable of sustaining growth.
Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector.
As rising global bond yields and escalating US-Iran tensions loom, the Indian stock market braces for a negative open. Analysts suggest a cautious approach with stock-specific strategies, identifying potential buy opportunities amid the chaos.
Market expert Raja Venkatraman shares his top stock picks for 18 August. Here’s his technical outlook and trade strategy.
Comprehensive Section Breakdown for IPCA Laboratories
Strategic Vision: Manufactures and supplies active pharmaceutical ingredients and formulations.
• Integrated manufacturing of APIs and formulations
• Broad portfolio of products across multiple therapeutic areas
• Extensive international distribution network
Revenue from operations increased ₹122 crore from Q1 FY2026-27 and was up from ₹2,557 crore in Q2 FY2025-26. Total expenses rose 5.5% QoQ to ₹2,364 crore, faster than the 4.4% revenue increase. Other expenses increased 11.9% to ₹805 crore, and finance costs rose to ₹12.6 crore from ₹11.9 crore.
Profit before exceptional items and tax was ₹571 crore, marginally below ₹572 crore in Q1 FY2026-27 and 27.0% above Q2 FY2025-26. The sequential comparison shows that higher revenue did not translate into growth in this pre-exceptional profit measure.
IPCA recorded an exceptional charge of ₹24.3 crore before tax, compared with no exceptional item in Q1 FY2026-27. Profit before tax fell 4.4% QoQ to ₹547 crore. Tax expense increased 4.3% to ₹155.6 crore, including current tax of ₹147.4 crore, up 10.9% sequentially.
Profit for the period was ₹389 crore, down from ₹424 crore in Q1 FY2026-27 but up 38.8% from ₹281 crore in Q2 FY2025-26. Earnings per share were ₹14.79, compared with ₹15.84 in Q1; trailing-12-month EPS was ₹55.28.
At 30 September 2026, current borrowings were ₹559 crore and noncurrent borrowings ₹67 crore, down from ₹595 crore and ₹109 crore, respectively, at 31 March 2026. They were also below the corresponding balances at 30 September 2025: ₹805 crore current and ₹400 crore noncurrent.
Inventories increased to ₹2,938 crore from ₹2,731 crore at 31 March 2026 and ₹2,516 crore at 30 September 2025. Trade receivables rose to ₹2,395 crore from ₹2,014 crore at 31 March 2026, while trade payables increased to ₹1,074 crore from ₹940 crore. Total current assets were ₹6,924 crore at 30 September 2026.
Category: Manufacturing
The company develops and produces a wide range of formulations and APIs, catering to various therapeutic areas such as pain management, rheumatology, antimalarials, and hair care.
Key Products & Services: Azifast • Azibact • Bisotrol • Bronchosolvin • Calchek • Cardoz • Cartiflex • Celedol • Clarbact
Core Thesis: The company leverages its integrated manufacturing capabilities to produce a diverse portfolio of pharmaceutical products for global markets.
• Integrated Manufacturing: The company maintains formulation facilities in several Indian states, enabling the production of both APIs and finished formulations. • Global Market Reach: IPCA's products are distributed internationally across the Americas, Africa, Asia, Australia, and Europe. • Diverse Therapeutic Areas: The company caters to a wide range of therapeutic areas including pain management, rheumatology, antimalarials, and hair care.